$1.97
0.01 (+0.51%)
Threshold Pharmaceuticals, Inc. (THLD)
CAPS Rating:
A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.
Recs
0
phase 3...did all the research
Recs
0
Pancreatic cancer is hard to show survival. Refractory pancreatic cancer is impossible to survival.
Recs
2
Trials look positive for pancreatic cancer and they may resume clinical research for prostate cancer.
Recs
2

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 4 of 4